Skip main navigation

Home > Search Results

Main contents starts here

Search Results

41 - 60 of about 80

Total 80 documents found.

  •  
  • R&D Overview
  • R&D; In the hopes of delivering at the earliest possible date the new drugs that are eagerly awaited by patients, Takeda is, being guided by the MPDRAP strategy, committed to the development of new drugs by focusing our management resources on the four core therapeutic areas.
  • Takeda Pharmaceutical Company Limited
  • Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan, and one of the global leaders of the industry. Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products.
  • Ethical Drugs
  • Products by Therapeutic Category: The following prescription drugs are listed for physicians and other healthcare professionals. These products may not be available in all countries. Also, the brand names, indications and uses may differ between countries.
  • Takeda as a World-Class Partner
  • The Takeda Group, which sells its 4 original international strategic products in major countries, is appreciated as a global alliance partner. Takeda cherishes its relationships of mutual trust with its partners and develops their ideas and/or compounds into global products by taking advantage of our original research and development and sales capabilities.
  • Takeda's Licensing Activities
  • To deliver innovative new drugs longed for by patients, doctors, and medical service providers as early as possible, Takeda defines its alliance and licensing activities as reinforcement measures to complement its proprietary research and development pipelines.
  • 4 M e s s a g e Yasuchika Hasegawa President & CEO Message to Stakeholders 5 Takeda's challenge is to realize its goal of becoming a "world-class pharmaceutical company." In the fiscal year ended March 31, 2009 (fiscal 2008), Takeda made significant progress toward realizing this goal through its largest ever strategic investment. In the pursuing year, the Company successfully integrated the world-class biopharmaceutical firm Millennium Pharmaceuticals, Inc. (Millennium) into the Takeda Group, based on a medium-to-long-term growth strategy of developing our core next-generation business in oncology. In addition to this, Takeda successfully realigned its operating structure in the world's largest pharmaceutical market, the U.S., through the division of TAP Pharmaceutical Products Inc. (TAP)a 30-year joint venture with Abbott Laboratories. Following the consolidation of TAP as a wholly-owned subsidiary, the sales and marketing functions of TAP were merged into our U.S. subsidiary Takeda Pharmaceuticals North A
  • Special Feature_2 An Outstanding Oncology Strategy 2008 was a remarkable year of progress for Takeda's oncology strategy through the inclusion of Millennium within the Takeda Group. In Millennium's first year as a Takeda organization and as leader of Takeda's global oncology strategy, Takeda Group's clinical oncology programs were successfully transferred to Millennium, and new medicines from the various discovery sites in Tsukuba, Osaka, San Francisco and San Diego were able to advance into the clinic. This close partnership with Takeda's global network has allowed for a smooth transition for Millennium to become The Takeda Oncology Company. The combined oncology pipeline of Takeda and Millennium could bring significant advances in treating patients with cancer. While many challenges remain in an increasingly competitive environment, Takeda Group is well poised for success. 18 (From left): Zhi Li, Ben Knight, Millennium Pharmaceuticals, Inc. Focused on Millennium's global oncology strategy, Takeda Group aim
  • - 1 - SUMMARY OF FINANCIAL STATEMENTS (Consolidated) Nine Months Results (April 1 to December 31, 2008) for the Fiscal Year Ending March 31, 2009 February 3, 2009 Takeda Pharmaceutical Company Limited Listed exchanges: Osaka, Tokyo, Nagoya, Fukuoka, Sapporo TSE Code: 4502 URL: Representative: http://www.takeda.co.jp Yasuchika Hasegawa, President Contact: Hirofumi Inoue, General Manager of Corporate Communications Department Telephone: +81 3 3278-2037 Scheduled date of securities report submission: February 13, 2009 1. Consolidated Financial Results (April 1 to December 31, 2008) for the Fiscal Year Ending March 31, 2009 (Millions of yen, rounded to the nearest million) (1) Consolidated Operating Results (aggregated) (Percentage figures represent changes from the same period of the previous year.) Net sales Operating income Ordinary income Net income ( million) change (%) ( million) change (%) ( million) change (%) ( million) change (%) Nine months ended December 31, 2008 1,202,760 239,884 254,578 168,573 Nin
  • 32 Pipeline represents ethical drugs under development, from the start of research to approval/launching. Clinical trials are conducted on humans for drugs for which basic research and nonclinical trials have already been completed. Through the procedures of three-phased clinical trials and following efficacy and safety evaluation, the pipelines are launched onto the market as new drugs after approval by the regulatory authorities. Implemented for a small group of healthy adults in order to evaluate safety and ADME (Absorption, Distribution, Metabolism, Excretion) of the drug. R&D Pipeline SYR-322 is a promising pipeline for the treatment of diabetes, following our core product: Actos. SYR-322 was founded by Takeda San Diego, Inc. (TSD) as a therapeutic agent for Type 2 diabetes, with a DPP-4* inhibitory action. In December 2007, SYR-322 was submitted for a New Drug Application in the U.S. Major Promising Pipelines as Next-Generation Core Products ■Anti-Diabetic Drug: SYR-322 TAK-491 is positioned as a succ
  • 22 Europe R&D in In order to help you further deeply understood Takeda's "current" and "future" globalization, a special feature in terms of our European operations is introduced in this section over six pages. Takeda has responded to industry trends, namely the socalled "integration of the global pharmaceutical market," from an early stage, since advancing to establish structures of R&D and the Japan-U.S.-Europe tripolar marketing functions. In Europe, we have been promoting following various approaches to establish our operating base. In fiscal 2006, we launched Takeda Cambridge Limited (TCB), which is anticipated to play a role in the global R&D network, as well as Takeda Pharmaceuticals Europe Limited (TPEU), which supervises the overall sales activities of Takeda's six subsidiaries in Europe. In addition, we also have been proactively participating in CSR activities, aiming to make further contributions to our stakeholders. Takeda Pharmaceuticals Europe Limited (U.K.) Takeda Cambridge Limited Takeda Glo
  • 4 Message Kunio Takeda Chairman Yasuchika Hasegawa President To Our Stakeholders 5 Focused on Takeda's goal of "growth towards a worldclass pharmaceutical company," as set forth in the 2006-2010 Medium-Term Plan, and maximizing the advantages of our corporate philosophy of "Takeda-ism = Integrity," Takeda continues to implement a variety of strategies in our business operations. The foremost of those strategies is the "Enhancement of the R&D Pipeline," by achieving sustained growth through the discovery and development of in-house products and the strategic investment of resources in high priority research areas. Furthermore, Takeda continues to reinforce its R&D pipeline through alliancessuch as the in-licensing of products and technologiescorporate acquisitions and product life-cycle management to maximize the value of marketed products. Through these efforts, Takeda's pipeline now has greater depth and in December 2007, we successfully submitted two New Drug Applications (NDA) in the U.S. for the anti-dia
  • 40 Setting Blopress on a Further Upward Trajectory Despite the difficult market circumstances, net sales of ethical drugs in the Japanese market reached 529.7 billion (a 2.9 percent increase over the previous year) and firmly maintaining the top market share in Japan. Net sales of the anti-hypertension drug: Blopress (generic name: candesartan cilexetil)our ultimate growth driverreached 137.1 billion (a 6.1 percent increase over the previous year), obtaining the top sales position among all the ethical drugs sold in Japan for the third consecutive year. In November 2007, the study results of HIJ- CREATEa large scale clinical trialwere released at the AHA: the American Heart Association's Scientific Sessions 2007 and the outcome showed that therapy based on Blopress significantly inhibits the incidence of major adverse cardiovascular events of new-onset patients with diabetes and those with impaired renal function. The implementation of HIJ-CREATE was targeted at coronary artery disease patients with hyperten
  • 61 REVIEW OF OPERATIONS AND FINANCIAL CONDITION Takeda Pharmaceutical Company Limited and Subsidiaries Year ended March 31, 2007 (Fiscal 2006) In Japan, the ethical drug market recorded negative growth for the first time in six years under the tough environment due to implementation of measures specifically promoting the use of generic drugs, and also to special price reductions and re-pricing, for those drugs that have generic versions, in addition to the usual price revisions under the National Health Insurance (NHI) in April 2006. For the future, it is estimated that the market growth will remain as low as the level ranging from one through two percent (1%-2%) under the environment in which the measures for constraint of expenditures for drugs will be promoted as indicated by ongoing discussion on the possibility of an annual revision of NHI drug prices instead of current biannual frequency, the reduction of drug prices separately from the actual market prices, and an introduction of prospective payment s
  • Takeda positions lifestyle-related diseases, oncology and urological diseases (including gynecological disorders), central nervous system diseases (including bone and joint diseases) and gastroenterological diseases as the four core therapeutic areas and has been promoting efforts based on the Tikarakobu Research Strategy, by reestablishing research strategies geared toward achieving our goal of the 2006-2010 Medium-Term Management Plan. The Tikarakobu Research Strategy aims to balance the "research resources concentration" and the "diversification of risk" by focusing and enriching the research themes in the strategy via the setting of drug categories which should be prioritized, and with the external environment, such as market and research trends, as well as the our strength, including the previous R&D achievements of the company, in mind. Through this initiative, we devote all our resources to achieving the final goal of launching new products onto the market, while effectively utilizing research resourc
  • 72 Millions of yen Thousands of U.S. dollars (Note 1) ASSETS 2007 2006 2007 Current assets: Cash and cash equivalents 1,647,694 1,626,235 $13,963,508 Marketable securities (Note 5) 92,342 243,285 782,559 Short-term investments 59,900 507,627 Notes and accounts receivable Trade notes 20,695 21,137 175,381 Trade accounts 232,639 207,887 1,971,517 Due from affiliates 8,641 7,656 73,229 Allowance for doubtful receivables (535) (309) (4,534) Total 261,440 236,371 2,215,593 Inventories (Note 6) 105,307 98,258 892,432 Deferred tax assets (Note 12) 139,223 135,019 1,179,856 Other current assets 51,807 32,802 439,044 Total current assets 2,357,713 2,371,970 19,980,619 Property, plant and equipment (Note 7): Land 62,271 44,853 527,720 Buildings and structures 256,546 247,106 2,174,119 Machinery and equipment 233,693 218,161 1,980,449 Tools and fixtures 63,191 61,888 535,517 Construction in progress 4,987 20,260 42,263 Total 620,688 592,268 5,260,068 Accumulated depreciation (382,242) (376,598) (3,239,339) Net property

Pages:[1] [2] [3] [4]   Next

Page Top